Q/C Technologies, Inc. Files 8-K: Material Agreements & Equity Changes
Ticker: QCLS · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Q/C Technologies, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001, $1,000, $5.00, $7.50, $10.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-securities, corporate-governance
TL;DR
Q/C Tech 8-K: New deals, stock changes, exec moves. Keep an eye on this.
AI Summary
On September 30, 2025, Q/C Technologies, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and material modifications to the rights of security holders. Additionally, there were changes in directors or officers and compensatory arrangements.
Why It Matters
This 8-K filing indicates significant corporate actions, including new agreements and potential changes in equity structure, which could impact investors and the company's strategic direction.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, unregistered equity sales, and modifications to security holder rights, suggesting potential shifts in the company's financial and operational landscape.
Key Players & Entities
- Q/C Technologies, Inc. (company) — Filer
- September 30, 2025 (date) — Date of earliest event reported
- 1185 AVENUE OF THE AMERICAS (address) — Business and Mail Address
- NEW YORK (location) — Business and Mail City
- DE (location) — State of Incorporation
- TNF Pharmaceuticals, Inc. (company) — Former Company Name
- MyMD Pharmaceuticals, Inc. (company) — Former Company Name
- Akers Biosciences, Inc. (company) — Former Company Name
FAQ
What specific material definitive agreement was entered into by Q/C Technologies, Inc. on September 30, 2025?
The filing states that Q/C Technologies, Inc. entered into a 'Material Definitive Agreement' on September 30, 2025, but the specific details of this agreement are not provided in the provided text.
What is the nature of the unregistered sales of equity securities reported in this 8-K?
The filing indicates 'Unregistered Sales of Equity Securities' occurred, but the specific details, including the amount and terms of these sales, are not elaborated in the provided text.
What modifications were made to the rights of security holders?
The filing mentions 'Material Modifications to Rights of Security Holders,' but the specific nature of these modifications is not detailed in the provided text.
Were there any changes in directors or officers reported?
Yes, the filing lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as an item information, indicating potential changes in company leadership or compensation.
What was Q/C Technologies, Inc. formerly known as?
Q/C Technologies, Inc. was formerly known as TNF Pharmaceuticals, Inc. (name changed July 25, 2024), MyMD Pharmaceuticals, Inc. (name changed April 20, 2021), and Akers Biosciences, Inc. (name changed April 13, 2017).
Filing Stats: 1,851 words · 7 min read · ~6 pages · Grade level 14.3 · Accepted 2025-10-03 17:28:48
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share QCLS The Nasdaq Capital M
- $1,000 — 0.001 per share, with a stated value of $1,000 per share (the "Preferred Stock"), and
- $5.00 — of Common Stock at an exercise price of $5.00 per share (the "First Tranche Warrant")
- $7.50 — of Common Stock at an exercise price of $7.50 per share (the "Third Tranche Warrant")
- $10.00 — es of Common Stock at exercise price of $10.00 per share (the "Fourth Tranche Warrant"
Filing Documents
- form8-k.htm (8-K) — 54KB
- ex3-1.htm (EX-3.1) — 17KB
- ex4-1.htm (EX-4.1) — 108KB
- ex10-1.htm (EX-10.1) — 41KB
- ex10-2.htm (EX-10.2) — 81KB
- 0001493152-25-016927.txt ( ) — 516KB
- qcls-20250930.xsd (EX-101.SCH) — 3KB
- qcls-20250930_lab.xml (EX-101.LAB) — 33KB
- qcls-20250930_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Q/C TECHNOLOGIES, INC. Date: October 3, 2025 By: /s/ Joshua Silverman Name: Joshua Silverman Title: Executive Chairman